Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2025-12-25 @ 2:32 AM
NCT ID:
NCT01854034
Eligibility Criteria:
Inclusion Criteria:
* Histologically or cytologically confirmed stage IV or recurrent NSCLC
* Measurable disease by RECIST 1.0
* Must have received at least one prior line of therapy for advanced lung cancer (no maximum number)
* Life expectancy of at least 12 weeks
Exclusion Criteria:
* Pregnant or breastfeeding
* Radiation within 2 weeks
* Cytotoxic chemotherapy or monoclonal antibodies within 4 weeks
* EGFR tyrosine kinase inhibitor within 2 weeks
* Other small molecule inhibitor within 2 weeks
* Experimental treatment within 30 days
* Prior treatment with any HSP90 or HDAC inhibitor compound
* Known and untreated brain metastases
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to AUY922
* Unresolved diarrhea greater than or equal to CTCAE version 4, grade 1
* Major surgery within 2 weeks of starting study drug or have not recovered from side effects of surgery
* Known disorders due to a deficiency in bilirubin glucuronidation
* Requiring use of therapeutic doses of warfarin (Coumadin)
* History of long QT syndrome
* History of clinically manifest ischemic heart disease, heart failure or left ventricular dysfunction
* Clinically significant ECG abnormalities
* Other clinically significant heart disease
* Currently receiving treatment with any medication which has a relative risk of prolonging the QTc interval or inducing Torsades de Pointes
* On a cardiac pacemaker
* Concurrent malignancies or invasive cancers diagnosed within 3 years except for adequately treated basal cell cancer of the skin or in situ cancer of the cervix
* Known to be HIV positive
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01854034
Study Brief:
Protocol Section:
NCT01854034